Modality
Radioligand
MOA
KIF18Ai
Target
CD38
Pathway
Apoptosis
AS
Development Pipeline
Preclinical
~Jun 2024
→ ~Sep 2025
Phase 1
Dec 2025
→ Apr 2026
Phase 1Current
NCT03313636
391 pts·AS
2025-12→2026-04·Terminated
391 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-04-112w awayPh2 Data· AS
Trial Timeline
2026Q2
P1/2
Termina…
Catalysts
Ph2 Data
2026-04-11 · 2w away
AS
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03313636 | Phase 1/2 | AS | Terminated | 391 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 |